Our focus is deeply rooted
in fibrotic lung disease

Upcoming events

2020-12-15

DNB Nordic Healthcare Conference

2021-02-10

Swiss Nordic Bio

Read more

Latest news

See all

Idiopathic Pulmonary Fibrosis (IPF) – weathering the pandemic

By Rohit Batta, CMO of Vicore Pharma Not being able to go out… Read More

Untangling the dualistic components of the RAS in PF the Yin and Yang

The Renin-Angiontensin System (RAS) has been studied for nearly 100 years, but there… Read More

About us

Vicore is a Swedish rare disease company focused on fibrotic lung disease and related indications. The company currently has two drug development programs, VP01 and VP02. VP01 aims to develop the substance C21 for the treatment of idiopathic pulmonary fibrosis (IPF), pulmonary fibrosis in systemic sclerosis (SSc) and COVID-19. VP02 is based on a new formulation and delivery route of an existing immunomodulatory compound. VP02 focuses on IPF with regards to both the underlying disease and the severe cough associated with IPF. VP01 and VP02 are also evaluated for other indications within the area of fibrotic lung disease.

The company’s shares (VICO) are listed on Nasdaq Stockholm’s main market.

Fibrotic lung disease

Idiopathic pulmonary fibrosis (IPF) is the most common type of pulmonary fibrosis and is a severe and devastating disease with no known cause. It is characterized by a shrinking of the lungs due to the irreversible formation of fibrosis (i.e. scar tissue) causing stiffness, an irreversible loss of lung function and difficulty in breathing.

Our Vision

Vicore’s vision is to remove the pain and suffering caused by fibrotic lung disease. As a company, we pride ourselves on our collaborative approach to science and are committed to working closely with the patient community, scientific experts and clinicians to find innovative solutions that meet their needs.